Q3 FY26: Standalone profit dips 13%; Rs 20 cr guarantee approved

Revenue declinedRelated-party transactionsContingent liabilities increasedResults View source PDF Explain this filing

HALEOSLABS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-1.3%Reaction day

₹1318.00

prior close

₹1275.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.5%-0.8% vs market

Pharmaceuticals peers, median of 157sector-0.6%-0.7% vs sector

On the reaction day the stock moved 0.8 pts less than Nifty Microcap 250 and 0.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.8

10m

-0.8

15m

-0.8

30m

-0.8

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-1.3-0.5-0.8-0.6-0.7

Next day

-1.4-2.0+0.6-1.4+0.1

-1.7-2.7+0.9-2.1+0.4

-1.9-1.7-0.2-1.6-0.3

-1.4-1.4+0.1-1.6+0.2

-2.4-2.8+0.5-2.5+0.1

-3.9-2.8-1.1-2.9-1.1

15d

-4.2-8.4+4.2-6.5+2.3

-4.2-9.1+4.9-6.6+2.4

-3.0-4.0+1.0-3.5+0.5

+28.2+2.6+25.6+0.7+27.5

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Haleos Labs posted Q3 FY26 standalone revenue of Rs 80.72 cr versus Rs 82.88 cr YoY, with net profit of Rs 5.41 cr versus Rs 6.23 cr (down 13%). Standalone nine month revenue fell 4 percent to Rs 237.6 cr; net profit dropped 17 percent to Rs 15.54 cr. Consolidated Q3 net profit rose 37 percent to Rs 6.65 cr on Rs 94.78 cr revenue. Board approved a Rs 20 crore corporate guarantee to RBL Bank for subsidiary Mahi Drugs ECB facility, subject to shareholder approval via postal ballot. Auditor Rambabu and Co gave an unmodified review opinion.

Likely market impact

Mixed bag with subsidiary-driven consolidated growth offsetting weak standalone numbers; new Rs 20 cr guarantee adds contingent liability pending shareholder nod.